Jefferies Maintains a 'Hold' on BioMed Realty (BMR); Q2 Review: Signs of Life

Jefferies maintains a 'Hold' on BioMed Realty (NYSE: BMR) price target of $22.00 (from $23.00).

Analyst, Omotayo Okusanya, said, "We maintain our rating on BMR stock given that 1) fundamentals continue to improve (i.e. same-store cash NOI growth increased in 2Q12 to +6.4%, with same-store leased percentage also up 460 bps year-over-year to 85.9%) and 2) BMR continues to put capital to work accretively via attractive investments."

FY EPS estimate lowered from $1.45 to $1.39.

For an analyst ratings summary and ratings history on BioMed Realty click here. For more ratings news on BioMed Realty click here.

Shares of BioMed Realty closed at $18.50 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• New Street Research Upgrades Micron Technology (MU) to Buy
• Stantec Inc. (STN:CN) (STN) PT Lowered to Cdn$169 at Desjardins